|
- Enzalutamide - Wikipedia
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer
- Enzalutamide: Uses, Dosage, Side Effects Warnings. - Drugs. com
Enzalutamide is a prescription medicine used to treat prostate cancer in men who have received surgery or hormone therapy to lower testosterone Enzalutamide is sometimes used when the cancer no longer responds to treatment, but has not spread to other parts of the body
- Enzalutamide (oral route) - Mayo Clinic
Enzalutamide is used to treat castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone), metastatic castration-sensitive prostate cancer (prostate cancer that has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower
- Enzalutamide - NCI - National Cancer Institute
Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t Spread FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers Targeted Cancer Therapies Hormone Therapy for Prostate Cancer Clinical Trials Accepting Patients
- XTANDI® (enzalutamide) | Advanced Prostate Cancer Treatment
XTANDI (enzalutamide) is a prescription medicine used to treat men with prostate cancer that: no longer responds to a hormone therapy or surgical treatment to lower testosterone OR has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone OR
- Enzalutamide: Indications, Side Effects, Warnings - Drugs. com
Easy-to-read patient leaflet for Enzalutamide Includes indications, proper use, special instructions, precautions, and possible side effects Skip to main content
- Xtandi (enzalutamide) - Uses, Side Effects, and More
Xtandi (enzalutamide) is commonly used to treat prostate cancer Xtandi may also be used for other conditions as determined by your health care provider How does Xtandi work (mechanism of
- FDA approves enzalutamide for prostate cancer
On November 16, 2023, the Food and Drug Administration approved enzalutamide (Xtandi, Astellas Pharma US, Inc ) for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical
|
|
|